In Wednesday's column we covered the huge win for T2 Biosytems (TTOO) which garnered FDA approval for a game changing bacterial panel that will dramatically reduce the time hospitals take to detect and treat sepsisSince then, the company has garnered some analyst praiseH.C. Wainwright upped their price target on TTOO to $14 a share from $8.50 prev...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.